Venture-capital firms are raising money at the highest rate in more than 15 years, even as the values of some once-hot startups have begun to cool.
Subscriber Content Read Preview
March withdrawals from Sequoia Fund, a mutual fund with a large stake in Valeant Pharmaceuticals, reached nearly $230 million through the end of last week.
Subscriber Content Read Preview
The SEC has intervened in a legal battle between mutual fund giant Vanguard Group and one of the company’s former lawyers, claiming the ex-employee should qualify for U.S. whistleblower protections.
Subscriber Content Read Preview
A flashy class of mutual funds that allow retail investors to tap into exotic strategies pioneered by hedge funds is colliding with the one force that threatens its growth: regulators on the hunt for systemic risk.
Subscriber Content Read Preview
Rollovers from 401(k)s to individual retirement accounts may slow as a coming Labor Department rule toughens standards for advisers.
Subscriber Content Read Preview
Putnam Investments took a bold step several years ago in naming each of its four ‘absolute return’ mutual funds for a specific performance target, but the company hasn’t often delivered on the funds’ aims.
Subscriber Content Read Preview
Directors of mutual funds should look to the failure of a distressed-debt fund last year and probe how prepared their portfolio managers are for the kind of turmoil that doomed the Third Avenue Focused Credit Fund, SEC Chairman Mary Jo White said Tuesday.
Subscriber Content Read Preview
After years of enjoying lighter-touch regulation under the Securities and Exchange Commission, the asset-management industry issued an unusual plea in 2014: Please regulate us.
Subscriber Content Read Preview
In China, which consumes more than a fifth of the global gold supply, the usual jewelry buying is taking a back seat to the buying of coins and bars by investors seeking a haven from global economic uncertainty.
Finance Watch
Subscriber Content Read Preview
Sequoia Fund benefited from a run-up in Valeant’s stock after Sequoia’s initial purchase in 2010. But the mutual fund’s performance declined recently when the drugmaker’s stock tumbled.
Subscriber Content Read Preview
The leader of a giant mutual fund that suffered large losses from its position in Valeant Pharmaceuticals has stepped down.
Subscriber Content Read Preview
Subscriber Content Read Preview
Exchange operator Bats Global Markets will buy ETF.com, according to a news release. Bats says in the release that the deal “adds to the proprietary market data and analytics that Bats offers to help market participants make educated trading and investment decisions.” ETF.com Chief Executive David Lichtblau will report directly to Bats' Head of U.S. […]